The Lancet, 385(9965), 351-361. ELSEVIER SCIENCE INC Swerdlow, D I, Preiss, D, Kuchenbaecker, K B, Holmes, M V, Engmann, J E L, Shah, T, Sofat, R, Stender, S, Johnson, P C D, Scott, R A, Leusink, M, Verweij, N, Sharp, S J, Guo, Y, Giambartolomei, C, Chung, C, Peasey, A, Amuzu, A, Li, K, Palmen, J, Howard, P, Cooper, J A, Drenos, F, Li, Y R, Lowe, G, Gallacher, J, Stewart, M C W, Tzoulaki, I, Buxbaum, S G, van der A, D L, Forouhi, N G, Onland-Moret, N C, van der Schouw, Y T, Schnabel, R B, Hubacek, J A, Kubinova, R, Baceviciene, M, Tamosiunas, A, Pajak, A, Topor-Madry, R, Stepaniak, U, Malyutina, S, Baldassarre, D, Sennblad, B, Tremoli, E, de Faire, U, Veglia, F, Ford, I, Jukema, J W & Price, J F 2015, ' HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials ', The Lancet, vol. 385, no. 9965, pp. 351-361 . https://doi.org/10.1016/S0140-6736(14)61183-1 Lancet, 385(9965), 351-361 The Lancet. Lancet Publishing Group The Lancet, 385(9965), 351. Elsevier Limited Lancet